Kurt Gustafson Sells 6,828 Shares of OmniAb (NASDAQ:OABI) Stock

OmniAb, Inc. (NASDAQ:OABI) CFO Kurt Gustafson sold 6,828 shares of OmniAb stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $1.70, for a total value of $11,607.60. Following the transaction, the chief financial officer owned 259,402 shares in the company, valued at $440,983.40. This trade represents a 2.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

OmniAb Stock Up 0.6%

OABI traded up $0.01 during midday trading on Tuesday, reaching $1.71. The company had a trading volume of 329,952 shares, compared to its average volume of 376,779. The business has a 50-day moving average of $1.90 and a two-hundred day moving average of $1.76. OmniAb, Inc. has a 1 year low of $1.22 and a 1 year high of $4.02. The company has a market cap of $246.16 million, a P/E ratio of -2.95 and a beta of 0.13.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of OmniAb in a report on Monday, December 22nd. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, OmniAb currently has a consensus rating of “Moderate Buy” and an average price target of $6.67.

Institutional Investors Weigh In On OmniAb

Several institutional investors and hedge funds have recently modified their holdings of the stock. Osaic Holdings Inc. lifted its holdings in shares of OmniAb by 214.4% in the second quarter. Osaic Holdings Inc. now owns 14,247 shares of the company’s stock worth $25,000 after buying an additional 9,716 shares in the last quarter. AQR Capital Management LLC bought a new stake in OmniAb in the 1st quarter valued at $25,000. BNP Paribas Financial Markets lifted its stake in OmniAb by 92.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 21,721 shares of the company’s stock worth $35,000 after purchasing an additional 10,438 shares in the last quarter. Cerity Partners LLC boosted its holdings in shares of OmniAb by 111.5% during the 2nd quarter. Cerity Partners LLC now owns 22,612 shares of the company’s stock valued at $39,000 after purchasing an additional 11,919 shares during the last quarter. Finally, SG Americas Securities LLC boosted its holdings in shares of OmniAb by 96.6% during the 4th quarter. SG Americas Securities LLC now owns 23,141 shares of the company’s stock valued at $43,000 after purchasing an additional 11,369 shares during the last quarter. Institutional investors own 72.08% of the company’s stock.

OmniAb Company Profile

OmniAb, Inc (NASDAQ: OABI) operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas.

Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021.